5-amino-1-(difluoromethyl)-8-(2-furyl)-3-(2-hydroxyethyl)-[1,2,4]triazolo[5,1-f]purin-2-one | 1367367-28-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: 5-amino-1-(difluoromethyl)-8-(2-furyl)-3-(2-hydroxyethyl)-[1,2,4]triazolo[5,1-f]purin-2-one
• 英文别名: 5-Amino-1-(difluoromethyl)-8-(furan-2-yl)-3-(2-hydroxyethyl)-[1,2,4]triazolo[5,1-f]purin-2-one
• CAS: 1367367-28-9
• 化学式: C₁₃H₁₁F₂N₇O₃
• 分子量: 351.272
• InChiKey: WFTVIMULDYQEQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST
  申请人：Advinus Therapeutics Limited

  公开号：EP2619211B1

  公开（公告）日：2015-09-09
• [EN] FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST<br/>[FR] COMPOSÉS TRICYCLIQUES FUSIONNÉS UTILISÉS COMME ANTAGONISTES DU RÉCEPTEUR DE L'ADÉNOSINE
  申请人：ADVINUS THERAPEUTICS LTD

  公开号：WO2012038980A2

  公开（公告）日：2012-03-29

  The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. [Formula should be inserted here] The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor. Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, drug addiction, post traumatic stress disorder and vascular injury and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.